Document is current
Any future updates will be listed below
-
Authors
Bacharach, Jason
Kannarr, Shane R.
Verachtert, Anthony
Gupta, Preeya K.
Razeen, Moataz
Cavet, Megan E.
Vittitow, Jason L.
Lang, Jacob
Chester, Thomas M.
Ziemanski, Jillian F.
White, Darrell E.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06309953 at ClinicalTrials.govDocuments that mention this clinical trial
Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study
https://doi.org/10.1007/s40123-025-01097-z
-
Funding
Funding for this research was provided by:
Bausch + Lomb, Rochester, NY, USA (study funding, Rapid Service Fee)
Bausch + Lomb, Bridgewater, NJ, USA (Funding for editorial/writing assistance)
- License Information
-
More Information
Article History
Received: 11 November 2024
Accepted: 24 January 2025
First Online: 22 February 2025
Declarations
:
: Jason Bacharach reports being a consultant and conducting research for Bausch + Lomb. Shane R. Kannarr reports serving as a consultant, being a speaker, or conducting research for Alcon, Allergan, Bausch + Lomb, CooperVision, Essilor, Johnson & Johnson Vision, Novartis, Ocuphire Pharma, RVL Pharmaceuticals, Sight Sciences, Tarsus Pharmaceuticals, Vision Source, and Visus Therapeutics. Anthony Verachtert reports nothing to disclose. Preeya K. Gupta reports serving as a consultant for Alcon, Aldeyra Therapeutics, Inc, Allergan, Azura, Bausch + Lomb, Dompé, Expert Opinion, HanAll Biopharma, Johnson & Johnson Vision, Kala Pharmaceuticals, Mazado, Inc, Nordic Pharma, Ocular Science, Oculis, Orasis, ScienceBased Health, Sight Sciences, SpyGlass Pharma, Surface Ophthalmics, Tarsus Pharmaceuticals, TearClear, Théa Pharma, Tissue Tech, Trukera Medical, Viatris, Visionology, Vital Tears, and Zeiss; and having stock options in Azura, Expert Opinion, Orasis, SpyGlass Pharma, Surface Ophthalmics, Tarsus Pharmaceuticals, TearClear, and Visionology. Moataz Razeen, Megan E. Cavet and Jason L. Vittitow are employees of Bausch + Lomb. Jacob Lang reports serving as a consultant to Alcon, Allergan, Aldeyra Therapeutics, AOS, AscuelaTech, Avellino, Bausch + Lomb, Dompé, Envision Biomedical, Horizon, Kala Pharmaceuticals, Novartis, Orasis, Oyster Point Pharma, Science Based Health, Scope, Sight Sciences, Sun Pharmaceutical Industries, Tarsus, Théa Pharma, Trukera Medical, and Zeiss; and as a speaker for Dompé, Oyster Point Pharma, and Sun Pharmaceutical Industries. Thomas M. Chester reports serving as a consultant/speaker for Bausch + Lomb, Sight Sciences, Tarsus, and Viatris. Jillian F. Ziemanski reports receiving research support from Bausch + Lomb. Darrell E. White reports serving as a consultant and speaker to Bausch + Lomb.
: The study was approved by the Advarra Institutional Review Board (IRB Registration number 00000971). This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, and all patients provided informed consent to participate in the study.
